title: Immunoconjugates: current status and future potential.
abstract: Whilst the concepts involved in immunoconjugates go back two centuries to the ideas of Ehrlich; it was only in the early 1980s that biotechnology gave us the tools to make pure immunoconjugates, in quantities sufficient for clinical studies [Garnett, M.C. (2002) "Targeted drug conjugates: principles and progress". Advanced Drug Delivery Reviews, 53, 171-216]. The early problems with immunogenicity that antibodies encountered in the clinic were addressed, in part by chimeric antibodies and later with humanised antibodies. At this time a number of different approaches were seriously evaluated for immunoconjugates, all with significant industrial backing, particularly from the emerging biotechnology companies.
authors.forename: M
authors.initials: M
authors.lastname: Eaton
mesh_terms: D016503:Drug Delivery Systems; D004345:Drug Industry; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology*; D014118:Toxins, Biological / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D018796:Immunoconjugates; D014118:Toxins, Biological